Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

Two randomized trials in China find that intra-arterial thrombolysis with urokinase or tenecteplase does not significantly ...

Values are mean ± SD, or N(%). ICU: intensive care unit, PTA: percutaneous transluminal angioplasty. In the AL group, 41 patients (61.4%) received additional treatment. Seven patients (10.0%) received ...

Pleasanton, California - BosterBio's expertise in antibody production and its exceptional technical support and educational ...

a Based on the 2003 Red Book average wholesale price of $538.42 per 250,000-IU vial and $0.17 and $0.05 per syringe and cap, respectively.

India: Emerging evidence highlights the potential role of serum soluble urokinase-type plasminogen activator receptor (suPAR) as a valuable biomarker for diagnosing and monitoring chronic obstructive ...

Monopar Therapeutics Inc.’s MNPR share price has surged by 15.06%, which has investors questioning if this is right time to sell.

EPICC HPV Elimination Partnership being supplied PROCEEDxFLOQ QAPs to Support Test Accuracy MISSISSAUGA, Ontario and ...

Dr. Li presented the results of a network meta-analysis comparing new-generation thrombolytic agents in acute ischemic stroke within 4.5 hours of onset, focusing on tenecteplase, reteplase, and ...